Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention
| Autor: | Jose Ramón Ruiz Arroyo, Jose Antonio Linares-Vicente, Paula Morlanes Gracia, Antonela Lukic, Ana Martínez Labuena, Daniel Meseguer González, Borja Simó Sánchez, Octavio Jiménez Melo, Pablo Revilla-Martí |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Ticagrelor medicine.medical_specialty Acute coronary syndrome Percutaneous Abciximab medicine.medical_treatment 030204 cardiovascular system & hematology 03 medical and health sciences Percutaneous Coronary Intervention 0302 clinical medicine Internal medicine medicine Humans Platelet business.industry Percutaneous coronary intervention Hematology General Medicine Tirofiban Middle Aged medicine.disease Treatment Outcome 030104 developmental biology Cardiology ST Elevation Myocardial Infarction Platelet aggregation inhibitor Female business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Platelets. 33:265-272 |
| ISSN: | 1369-1635 0953-7104 |
| DOI: | 10.1080/09537104.2021.1881953 |
| Popis: | Platelet glycoprotein IIb/IIIa inhibitors (GPIs) have been part of the adjuvant treatment of acute coronary syndrome for years. However, real-life data regarding the efficacy and safety of GPIs under the current indications are lacking in the setting of potent platelet inhibition. The objectives were to assess the efficacy and safety of abciximab versus tirofiban in patients with ST-elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) and pretreated with ticagrelor, and to identify independent predictor factors of efficacy, bleeding and platelet drop. Three hundred sixty-two patients were divided by GPI administered. Clinical, laboratory, angiographic and outcome characteristics were compared. The primary objective was a composite efficacy endpoint (death from any cause, nonfatal myocardial infarction and nonfatal stroke) at 30 days. The secondary objectives were its individual components, safety (bleeding) and the impact on platelet count during hospital stay. The composite efficacy endpoint was similar in the abciximab and tirofiban groups (6.1% vs 7.3% |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|